Remember that the Financial Analyst Meeting BioAlliance Pharma? all menus - Confidential Small Caps
BIOALLIANCE PHARMA (FR0010095596) issued yesterday after the market, its financial results for H1 2013. At the Financial Analyst Meeting held this morning - and which I visited all menus - the direction is reversed recent developments and outlook.
In H1 2013, sales reached 0.8 million, representing a steady increase over H1 2012. Sales come mainly from product licensing (royalties) of its Loramyc.
The R & D increased by 8% (5.21 million) compared to H1 2012. The company recorded the last half of a loss of 7.5 million, an improvement from a loss of 7.8 million recorded in H1 2012.
The cash amounted to 30 June 2013 of 11.9 million, against 14.5 million at end 2012. On July 2, BIOALLIANCE had raised 8.4 million euros through a capital increase. Nicolas Fellmann, CFO, said during the meeting he remained SFAF 1,265,000 securities to pull the line PACEO initiated in February 2013.
Loramyc on a Phase III began in Japan in March 2013, 100 patients are recruited to the study. all menus Regarding Sitavig (treatment of recurrent herpes labialis), discussions with potential partners continue. On this point, BIOALLIANCE is spirited look that is the best financial balance. The challenge is a commercial partner and compatibility between BIOALLIANCE. On Validive (treatment of oral mucositis), the preliminary results of Phase II will be released in H2 2014.
On Livatag (liver cancer), which is a priority for the group because of its potential blockbuster status - is greater than $ 1 billion annual sales - a meeting of the committee of independent experts (DSMB meeting) is expected the United States for the fourth quarter of 2013, with an announcement on the extension to the U.S. under H1 2014 agreement.
Related Articles: July 22, 2013 - Successful AK BIOALLIANCE all menus PHARMA June 28, 2013 - Bioalliance Pharma: Capital increase of 8 million July 13, 2012 - NEWS 2158: Good news for Bioalliance Pharma March 1, 2012 - 1436 NEWS: Collection of Bioalliance Pharma March 1, 2012 - NEWS 1436: Collection of Bioalliance Pharma 13 July 2012 - NEWS 2158: Good news for Pharma Bioalliance June 28, 2013 - Bioalliance Pharma: Capital increase of 8 million euros 22 July 2013 - Successful AK BIOALLIANCE PHARMA September 20, 2013 - Key points to financial analysts BioAlliance Pharma?
Sacha Pouget has 10 years experience on the trading floor at BNP Paribas, all menus Royal Bank of Canada and Credit Agricole Cheuvreux. He focused on growth all menus stocks of the health sector and especially small biotechnology companies, which have the strongest catalysts increase in minimum time to market all menus with a controlled risk. Author of a book on investments in the health sector, he developed methods for analysis and selection of unique values directly inspired by the best traders. all menus Its Portfolio Health appreciated 42% in the third quarter of 2012. His website: http://sachapouget.com/
Register for free to Small Caps Confidential Email SUBSCRIBE * We do not share your e-mail address. View our privacy policy
News NEWS 4176: Over the last 5 years up to MGI Digital Graphic 4175 NEWS: New drop Inside Secure NEWS 4174: High last year for Bourse Direct NEWS 4173: Return losses for Aegis NEWS 4172: Investors are positioned on Chargers NEWS 4171: Trigano accelerates its growth NEWS 4170: Paris expected to decline Genoway sought before the publication of its 4169 results NEWS: Esi Group under the 4168 consensus NEWS: Avanquest resists NEWS 4167: More than 5 years up to MGI COUTIER NEWS 4166: CIS better than expected
2011-2013 Agora Publications | The contents of this site may be published without the express written consent of Agora Publications. | Customer Service: 01 44 59 91 11 Monday to Friday from 9h to 17h or by email: service-clients@publications-agora.fr | Legal | Help | Terms | Contact
BIOALLIANCE PHARMA (FR0010095596) issued yesterday after the market, its financial results for H1 2013. At the Financial Analyst Meeting held this morning - and which I visited all menus - the direction is reversed recent developments and outlook.
In H1 2013, sales reached 0.8 million, representing a steady increase over H1 2012. Sales come mainly from product licensing (royalties) of its Loramyc.
The R & D increased by 8% (5.21 million) compared to H1 2012. The company recorded the last half of a loss of 7.5 million, an improvement from a loss of 7.8 million recorded in H1 2012.
The cash amounted to 30 June 2013 of 11.9 million, against 14.5 million at end 2012. On July 2, BIOALLIANCE had raised 8.4 million euros through a capital increase. Nicolas Fellmann, CFO, said during the meeting he remained SFAF 1,265,000 securities to pull the line PACEO initiated in February 2013.
Loramyc on a Phase III began in Japan in March 2013, 100 patients are recruited to the study. all menus Regarding Sitavig (treatment of recurrent herpes labialis), discussions with potential partners continue. On this point, BIOALLIANCE is spirited look that is the best financial balance. The challenge is a commercial partner and compatibility between BIOALLIANCE. On Validive (treatment of oral mucositis), the preliminary results of Phase II will be released in H2 2014.
On Livatag (liver cancer), which is a priority for the group because of its potential blockbuster status - is greater than $ 1 billion annual sales - a meeting of the committee of independent experts (DSMB meeting) is expected the United States for the fourth quarter of 2013, with an announcement on the extension to the U.S. under H1 2014 agreement.
Related Articles: July 22, 2013 - Successful AK BIOALLIANCE all menus PHARMA June 28, 2013 - Bioalliance Pharma: Capital increase of 8 million July 13, 2012 - NEWS 2158: Good news for Bioalliance Pharma March 1, 2012 - 1436 NEWS: Collection of Bioalliance Pharma March 1, 2012 - NEWS 1436: Collection of Bioalliance Pharma 13 July 2012 - NEWS 2158: Good news for Pharma Bioalliance June 28, 2013 - Bioalliance Pharma: Capital increase of 8 million euros 22 July 2013 - Successful AK BIOALLIANCE PHARMA September 20, 2013 - Key points to financial analysts BioAlliance Pharma?
Sacha Pouget has 10 years experience on the trading floor at BNP Paribas, all menus Royal Bank of Canada and Credit Agricole Cheuvreux. He focused on growth all menus stocks of the health sector and especially small biotechnology companies, which have the strongest catalysts increase in minimum time to market all menus with a controlled risk. Author of a book on investments in the health sector, he developed methods for analysis and selection of unique values directly inspired by the best traders. all menus Its Portfolio Health appreciated 42% in the third quarter of 2012. His website: http://sachapouget.com/
Register for free to Small Caps Confidential Email SUBSCRIBE * We do not share your e-mail address. View our privacy policy
News NEWS 4176: Over the last 5 years up to MGI Digital Graphic 4175 NEWS: New drop Inside Secure NEWS 4174: High last year for Bourse Direct NEWS 4173: Return losses for Aegis NEWS 4172: Investors are positioned on Chargers NEWS 4171: Trigano accelerates its growth NEWS 4170: Paris expected to decline Genoway sought before the publication of its 4169 results NEWS: Esi Group under the 4168 consensus NEWS: Avanquest resists NEWS 4167: More than 5 years up to MGI COUTIER NEWS 4166: CIS better than expected
2011-2013 Agora Publications | The contents of this site may be published without the express written consent of Agora Publications. | Customer Service: 01 44 59 91 11 Monday to Friday from 9h to 17h or by email: service-clients@publications-agora.fr | Legal | Help | Terms | Contact
No comments:
Post a Comment